Drawing for SPLENDRIS

USPTO serial 90389507

SPLENDRIS

Reviewed by CopyMark Law Group

Reg. 6559649Status 700Renewal
Filing date
Status date
Registration date
Nov 16, 2021
Examiner
MURRAY, GEORGE WILLIAM
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with SPLENDRIS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*

Plus Government fees of $325

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Nazly Aileen Bayramoglu

Nazly Aileen Bayramoglu BAYRAMOGLU LAW OFFICES LLC1540 WEST WARM SPRINGS ROAD SUITE 100HENDERSON, NV 89014UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Chemico-pharmaceutical preparations, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Chemical preparations for pharmaceutical or medical purposes, namely, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Medicines for human purpose, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Medicated Troches, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the cerebrovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Active pharmaceutical ingredients in the nature of pharmaceutical preparations, which are used for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the cerebrovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Medicinal herbal preparations, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Biochemical medicines, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases, Pharmaceutical preparations for the treatment of heart rhythm disorders, Synthetic peptides for the treatment of cardiovascular disease; Dietetic substances adapted for medical use, namely, beverages and food in the nature of vitamin, protein, minerals, lecithin, glucose, amino acid, folic acid, fruit juice, fruit oil, honey, seaweed glue, fish oil, cod-liver oil, cubilose, restoratives, plant fibre, nutrition powder, nutrient capsule, nutrient tablets, mineral food-supplements used for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Drugs for medical purposes, namely, Pharmaceutical products for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the cerebrovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disordersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 17, 2026REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Nov 16, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 31, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 31, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 11, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 28, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 22, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 21, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 21, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 16, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 16, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 16, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 11, 2021DOCKASSIGNED TO EXAMINER—
Feb 26, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 21, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance